15 reports

  • ORPHAN AND RARE DERMATOLOGY DRUGS MARKET, GLOBAL, FORECAST REVENUE BY COMPANY (%), 2017-2024
  • ORPHAN AND RARE DERMATOLOGY DRUGS MARKET, GLOBAL, COMPANIES BY COMPOUND ANNUAL GROWTH RATE (%), 2017-2024

International ##: ##-## Journal of Clinical ##(##): ##-##. from: of Child Neurology; ##(##): ##-## ##(##): ## Journal of Pharmaceutics; ##(##): ##-## British Association of Dermatologists (2018).

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatological Treatment
  • Pharmaceutical
  • UCB S.A.
  • UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • UCB SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Summary UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases.It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company’s key medicines include Cimzia...

  • Healthcare
  • Neurological Disorder
  • Pharmaceutical
  • Therapy
  • UCB S.A.
  • UCB Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • UCB Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Summary UCB Inc (UCB), a subsidiary of UCB SA, is a healthcare solutions provider that offers therapeutics.The company develops products with an emphasis on central nervous system and immunology therapeutic domains. Its products include cimzia, vimpat, keppra XR, neupro, tussionex pennkinetic, metadate CD, and others.UCB’s...

  • Healthcare
  • Pharmaceutical
  • United States
  • UCB S.A.
  • Beryllium Discovery Corp, Pharmaceuticals & Healthcare, Deal Details
  • UCB Pharma Acquires Remaining Stake in Beryllium Discovery

Summary Beryllium Discovery Corp (Beryllium) is a research services providing company that offers structural biology services.The company provides main activities such as construct design, protein expression and purification, molecular and cell biology, crystallography, NMR spectroscopy, fragment screening, Surface Plasmon...

  • Pharmaceutical
  • United States
  • Deals & Alliance
  • UCB S.A.
  • UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations.The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The...

  • Neurological Disorder
  • Pharmaceutical
  • United States
  • Company Financials
  • UCB S.A.
  • AMPHASTAR PHARMA ACQUIRES INTERNATIONAL MEDICATION SYSTEMS FROM UCB PHARMA FOR USD7.7 MILLION
  • Jan 05, 2017: MC10 and UCB Complete Landmark Pharmaceutical / Technology Collaboration Evaluating Patient Monitoring in Parkinson's

Summary UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases.It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company’s key medicines include Cimzia...

  • Medical Device
  • Pharmaceutical
  • United States
  • Company Financials
  • UCB S.A.
  • NEWBRIDGE PHARMACEUTICALS TARGETS AND PARTNERS (2012 -YTD2016)
  • TARGETS AND PARTNERS

Project Synopsis: Datamonitor's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Project Description: Datamonitors' NewBridge...

  • Pharmaceutical
  • Company
  • Corporate Finance
  • Deals & Alliance
  • UCB S.A.
  • CLINICAL TRIALS BY SPONSOR TYPE
  • PROMINENT SPONSORS

GlobalData Clinical Trial Reports are generated using GlobalData' s proprietary database - Pharma Intelligence Center Clinical trials database.

  • Clinical Trial
  • Dermatological Condition
  • Pharmaceutical
  • Therapy
  • UCB S.A.
  • SEIZURES THERAPEUTICS CLINICAL TRIALS, GLOBAL, KEY SPONSORS, 2018*
  • CLINICAL TRIALS BY SPONSOR TYPE

The prominent features of this report are - ##.

  • Clinical Trial
  • Neurological Disorder
  • Pharmaceutical
  • World
  • UCB S.A.
  • PROMINENT SPONSORS
  • PARTIAL SEIZURE THERAPEUTICS CLINICAL TRIALS, GLOBAL, KEY SPONSORS, 2018*

## ## ## ## ## ## ## Inconclusive ## ## ## ## ## ## ## ## Not Achieved ## ## ## ## ## ## ## ## Partially Achieved Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2018 2018 t

  • Clinical Trial
  • Pharmaceutical
  • Therapy
  • World
  • UCB S.A.
  • DIVESTMENTS - DEAL REPORTS
  • DIVESTMENTS - DEAL REPORTS

UCB S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline’s UCB S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital...

  • Healthcare
  • Pharmaceutical
  • Therapy
  • Company
  • UCB S.A.
  • DIVESTMENTS - DEAL REPORTS
  • DIVESTMENTS - DEAL REPORTS

UCB S.A. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline’s UCB S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital...

  • Healthcare
  • Pharmaceutical
  • Therapy
  • Company
  • UCB S.A.
  • Prominent Sponsors
  • Clinical Trials by Sponsor Type

## ## ## ## ## ## Parexel International Corp ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## Eli Lilly and Company ## ## ## ## ## ## ## Johnson & Johnson ## ## ## ## ## ## ## Merck & Co Inc ## ## ## ## ## ## ##

  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • UCB S.A.
  • FINANCIAL DEALS ACTIVITY OVERVIEW
  • UCB S.A.: TOP DEALS 2013 - 2017YTD*

We also outperformed our recurring EBITDA* to net debt ratio target of ##:## - two years earlier than expected.

  • Pharmaceutical
  • United States
  • World
  • Company
  • UCB S.A.
  • UCB S.A., Key Facts
  • Other Locations & Subsidiaries

Suite ## Raffles City Shanghai Office Tower ## Tibet Road Central Shanghai SHA ## China Tel: +## ## ## Fax: +## ## ## UCB Pharma GmbH Geiselbergstrasse ##-## ## Stiege/ ## Stock Wien ## Austria Tel: +## ## ## Fax: +## ## ## UCB Farma Brasil L

  • Pharmaceutical
  • Therapy
  • United States
  • Company Operations
  • UCB S.A.